<?xml version="1.0" encoding="UTF-8"?>
<p id="Par2">Acute graft-versus-host disease (aGvHD) is the most important obstacle of haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) for treatment of patients with hematologic malignancies. In the last two decades, the results of Haplo-HSCT have been conspicuously improved due to effective prophylaxis strategies for aGvHD, such as in vivo T-cell depletion (TCD) with anti-thymocyte globulin (ATG) or posttransplant cyclophosphamide (PTCy) [
 <xref ref-type="bibr" rid="CR1">1</xref>, 
 <xref ref-type="bibr" rid="CR2">2</xref>].
</p>
